Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi James Anthony, I'm so sorry you are going through this and so very young. It' s true that some people benefit for years with chemo and targeted therapies. With the...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.